AU1200488A - Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci - Google Patents

Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci

Info

Publication number
AU1200488A
AU1200488A AU12004/88A AU1200488A AU1200488A AU 1200488 A AU1200488 A AU 1200488A AU 12004/88 A AU12004/88 A AU 12004/88A AU 1200488 A AU1200488 A AU 1200488A AU 1200488 A AU1200488 A AU 1200488A
Authority
AU
Australia
Prior art keywords
pharmaceutical
pci
diagnostic aid
inhibitor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU12004/88A
Other versions
AU617303B2 (en
Inventor
Norbert Heimburger
Klaus-Peter Radtke
Thomas Stief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL BEHRING GmbH
Original Assignee
CSL BEHRING GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL BEHRING GmbH filed Critical CSL BEHRING GmbH
Publication of AU1200488A publication Critical patent/AU1200488A/en
Application granted granted Critical
Publication of AU617303B2 publication Critical patent/AU617303B2/en
Assigned to CENTEON PHARMA GMBH reassignment CENTEON PHARMA GMBH Alteration of Name(s) in Register under S187 Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT
Assigned to AVENTIS BEHRING GMBH reassignment AVENTIS BEHRING GMBH Request to Amend Deed and Register Assignors: CENTEON PHARMA GMBH
Assigned to ZLB BEHRING GMBH reassignment ZLB BEHRING GMBH Request to Amend Deed and Register Assignors: AVENTIS BEHRING GMBH
Assigned to CSL BEHRING GMBH reassignment CSL BEHRING GMBH Request to Amend Deed and Register Assignors: ZLB BEHRING GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The suitability of protein C inhibitor as a pharmaceutical, that is as a therapeutic or in vivo diagnostic, and also as an in vitro diagnostic, and a composition containing this inhibitor is described. A process for the preparation of such a pharmaceutical or diagnostic is additionally given. Protein C inhibitor is particularly suitable for the therapy and diagnosis of angiogenic diseases or tumours.
AU12004/88A 1987-02-23 1988-02-22 Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci Expired AU617303B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873705745 DE3705745A1 (en) 1987-02-23 1987-02-23 PROTEIN C-INHIBITOR (PCI) AS A PHARMACEUTICAL AND IN VITRO-DIAGNOSTIC, METHOD FOR PRODUCING SUCH A PHARMACEUTICAL OR DIAGNOSTIC AND A MEDIUM CONTAINING PCI
DE3705745 1987-02-23

Publications (2)

Publication Number Publication Date
AU1200488A true AU1200488A (en) 1988-08-25
AU617303B2 AU617303B2 (en) 1991-11-28

Family

ID=6321571

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12004/88A Expired AU617303B2 (en) 1987-02-23 1988-02-22 Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci

Country Status (7)

Country Link
EP (1) EP0280135B1 (en)
JP (1) JP2725777B2 (en)
AT (1) ATE67672T1 (en)
AU (1) AU617303B2 (en)
CA (1) CA1322332C (en)
DE (2) DE3705745A1 (en)
ES (1) ES2040765T3 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423313B1 (en) * 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
JPH1160500A (en) * 1997-08-11 1999-03-02 Nippon Chem Res Kk Blood coagulation abnormal advance inhibitor
CA2410480A1 (en) * 2000-05-26 2001-12-06 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by retinoids
JP4852773B2 (en) 2004-10-15 2012-01-11 国立大学法人三重大学 Liver regeneration / restoration control agent
EP1894574A4 (en) * 2005-04-18 2011-05-18 Univ Mie Anti-cancer agent comprising protein c inhibitor
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757192B2 (en) * 1986-04-25 1995-06-21 旭化成工業株式会社 New DNA

Also Published As

Publication number Publication date
DE3705745A1 (en) 1988-09-01
DE3865035D1 (en) 1991-10-31
EP0280135A3 (en) 1988-10-05
CA1322332C (en) 1993-09-21
JP2725777B2 (en) 1998-03-11
EP0280135B1 (en) 1991-09-25
EP0280135A2 (en) 1988-08-31
ATE67672T1 (en) 1991-10-15
AU617303B2 (en) 1991-11-28
JPS63233927A (en) 1988-09-29
ES2040765T3 (en) 1993-11-01

Similar Documents

Publication Publication Date Title
ES2042725T3 (en) PROCEDURE FOR PREPARING 5-ALPHA-ESTERSA STEROID INHIBITORS.
GR3018825T3 (en) 3-Demethyl-4-fluoro-mevalonic-acid derivatives, process for their preparation, pharmaceutical preparations based on those compounds, their use and intermediates
PL317105A1 (en) Compositions containing dna and p53 damaging agents
IL97411A (en) Pharmaceutical formulations comprising hapten-modified diagnostic or therapeutic agents
EP0151989A3 (en) Means for the treatment of cardiac diseases
AU1170588A (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
HU895785D0 (en) Process for the preparation of compositions and medical preparations containing acid-resistent fibroplast growth activator for treating gastrointestinal ulcer
GR3006091T3 (en)
GR3006815T3 (en)
AU2742892A (en) An anticoagulant substance obtained from urine
EP0173663A3 (en) The use of a specific tumor associated antigen, sialosyllactotetraose, in diagnostic or therapeutic procedures related to cancer deseases
AU2807689A (en) Method for the treatment of body tissues and the administration of drugs thereto
GB2206796B (en) Medical instrument for therapy of hemorrhoidal lesions
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci
HU902004D0 (en) New trombolitic preparations
MX9200413A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR DIAGNOSIS OF SOFT TISSUE TUMORS.
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
ES8703742A1 (en) Sustained-release compositions, process for preparing them and suitable compositions for medical or veterinary use.
ZA894945B (en) Strontium salt,process for the preparation thereof and pharmaceutical compositions containing it
ZA81927B (en) Phenylpiperazine derivatives of 1,3,4-oxadiazolyphenols their preparation and therapeutic agents containing these compounds
EP1150703A4 (en) Chaperonin 10 and beta-interferon therapy of multiple sclerosis
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
AU3065789A (en) Clinical testing, monitoring and pharmaceutical compositions for treatment of auto-immune diseases
GR3005231T3 (en)
EP0257418A3 (en) Oxirane-pseudo-oligosaccharides, process for their synthesis, their use and pharmaceutical preparations

Legal Events

Date Code Title Description
PC Assignment registered

Free format text: CENTEON PHARMA GMBH

HB Alteration of name in register

Owner name: AVENTIS BEHRING GMBH

Free format text: FORMER NAME WAS: CENTEON PHARMA GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20010222 TO 20011222 IN WHICH TO PAY A RENEWAL FEE HAS BEEN LODGED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 20011222